
|Articles|October 8, 2014
- NSCLC (Issue 4)
- Volume 4
- Issue 1
The Importance of Biomarkers for Lung Cancer
Author(s)Fred R. Hirsch, MD, PhD
Fred R. Hirsch, MD, PhD, Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the importance of biomarkers for lung cancer.
Advertisement
Fred R. Hirsch, MD, PhD Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the importance of biomarkers for lung cancer.
Articles in this issue
about 11 years ago
The Implementation of Personalized Medicine for Lung Cancer Patientsabout 11 years ago
The Benefit of Treating Lung Cancer with Immunotherapyabout 11 years ago
The Cancer Genome Atlas Plays Role in Future Therapies for NSCLCabout 11 years ago
In Practice: Systemic Treatment for Metastatic NSCLCabout 11 years ago
Clinical Trial Profile: The OAK Studyabout 11 years ago
Optimizing of Therapeutic Sequencing Being Studied in NSCLCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5







































